Dr. Daniel Latt Presents Final Outcome From Chronic Heel Pain Study Using Guided Therapy Systems LLC’ Actisound Device At AOFAS 2016

MESA, Ariz., July 21, 2016 /PRNewswire/ -- Guided Therapy Systems (GTS), a world leader in ultrasonic therapy and imaging technologies, will be featured in a presentation given by Daniel Latt, MD PhD, Associate Professor of Orthopedic Surgery at the University of Arizona, at this year’s American Orthopedic Foot & Ankle Society (AOFAS) annual meeting on Saturday, July 23 at 11:50 a.m. EDT.

Dr. Latt will speak about the final results of a randomized controlled trial of intense therapeutic ultrasound (ITU) for the treatment of chronic plantar fasciitis. During the trial, Latt used Actisound, a device created by GTS that uses ITU technology to heal musculoskeletal injuries without breaking the skin. The device works by noninvasively creating small zones of thermal lesions within the connective tissue to stimulate the natural healing process.

“Plantar fasciitis is an extremely common cause of heel pain,” said Latt, “one in which ineffective healing of the overloaded plantar fascia - the firm band forming the arch of the foot - leads to severe heel pain with the first few steps in the morning and during activity”.

The initial treatment of plantar fasciitis, which includes medication, stretching and shoe inserts, is generally effective, but takes three to six months for patients to see improvement. This particular study was conducted to test whether ITU could speed the healing of chronic plantar fasciitis.

In their recently completed study comparing standard therapy plus ITU to standard therapy plus sham control, Dr. Latt’s team found that the ITU group had a greater and more rapid reduction of heel pain and perifascial lesion size as well as a more rapid return to function compared to the sham control group.

“Guided Therapy Systems is driving innovation within the musculoskeletal market with this product,” said Dr. Latt. “Actisound has given our patients substantial relief much quicker than standard treatments alone. We can say with confidence that high frequency ITU is effective in reducing pain and shortening recovery time, and hopefully will soon be a viable alternative to open surgery for patients with many forms of chronic tendonitis such as tennis elbow, golfer’s elbow, rotator cuff tendonitis, Achilles tendonitis and more.”

For more information on GTS and ITU technology, please visit http://www.guidedtherapy.com.

About Guided Therapy Systems

Guided Therapy Systems (GTS) is a leader in ultrasonic therapy and imaging. GTS is the first company to develop and commercialize products that combine ultrasound imaging with intense therapeutic ultrasound, offering physicians the ability to image and treat with the same equipment, thus targeting and evaluating tissue prior to, during and after a procedure. In 2004, GTS separated into two companies Ardent Sound, Inc. became the commercial manufacturer of diagnostic ultrasound imaging devices, while GTS incubates new commercial opportunities for its intense therapeutic ultrasound platforms. GTS brought intense therapeutic ultrasound to the forefront of the aesthetic device landscape through the creation of Ulthera the only energy-based technology with an FDA indication for non-invasive tissue lift. GTS expanded into skin care devices for the consumer market with the founding of Xthetix, Inc., which was acquired by a Fortune 100 consumer products company in 2011. Today GTS has over 250 patents issued, published, and pending in support of their imaging and Intense Therapeutic Ultrasound (ITU) technologies as they continue to create new ultrasound technologies that diagnose, treat and heal injury.

For additional information on the company, please visit http://www.guidedtherapy.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dr-daniel-latt-presents-final-outcome-from-chronic-heel-pain-study-using-guided-therapy-systems-actisound-device-at-aofas-2016-300302051.html

SOURCE Guided Therapy Systems

MORE ON THIS TOPIC